The human immunodeficiency virus (HIV) therapeutics market was worth an estimated $22.9 billion across the seven major markets (7MM; the US, France, Germany, Italy, Spain, UK and Japan) in 2019.
The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 2%, reaching $28 billion in 2029, according to data and analytics company GlobalData.
GlobalData’s latest report, HIV Therapeutics: Global Drug Forecast and Market Analysis to 2029, reveals that growth in the market will be driven by the entry of injectable therapies that can be administered intramuscularly or subcutaneously.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze